Biography for Eric Palmer
Eric Palmer, Senior Editor
Eric Palmer is a business and technology journalist with more than three decades of prize-winning experience as a reporter and editor with daily, weekly, monthly and online publications. He was healthcare reporter for The Kansas City Star before becoming deputy business editor for the daily newspaper. He spent eight years as editor of The Kansas City Business Journal, which had a strong emphasis on the healthcare industry. On the personal side, he is an avid fly fisherman, cooks and collects wine, and likes to travel with his family. Eric is based in Kansas City and can be reached at firstname.lastname@example.org.
Articles by Eric Palmer
Swiss contract manufacturer Siegfried Holding has fattened up its API manufacturing capabilities, having completed a deal to buy three production operations in Europe from BASF. The exchange, the German chemical giant says, allows it to narrow its focus on higher-margin pharma products.
The cleanup of the former American Cyanamid drug manufacturing site in Bridgewater, NJ, has been ongoing for decades. But the EPA this week presented Pfizer with a bill for its share of the cost of cleaning up the superfund site.
The U.K.'s Centre for Process Innovation (CPI) has completed and opened its £38 million ($57.5 million) facility devoted to the research and development of new process for manufacturing biologics.
Iodine is routinely used on patients ahead of operations to help protect against bacteria contamination. But what if the iodine itself is contaminated with a toxic chemical? That is the issue facing 3M, which is recalling thousands of cases of surgical applicators.
If a pharma plant closes because of an explosion or a natural disaster, well there is business interruption insurance for that. But if it closes to deal with issues after the FDA issues a Form 483 or a warning letter, then the drugmaker is on the hook for all of the costs. Now a couple of insurance companies say they will offer something to soften such blows.
Two years ago, Sun Pharma was before the U.S. Supreme Court defending a label for one of its generic drugs against claims that it didn't adequately warn against risks. Now the labels on some of its drugs are creating another kind of problem, leading to a recall of more than 216,000 bottles of drugs.
Mayne Pharma established a U.S. beachhead three years ago when it picked up Metrics Contract Services and took over its campus in North Carolina. Now the Australian drugmaker will broaden its footprint with a new manufacturing plant that will significantly expand its capacity.
CDMO Aesica says one of its U.K. plants will receive electricity from a proposed biomass plant that is expected to reduce greenhouse gas emissions equal to removing 25,000 cars from the U.K.'s roads over 20 years.
Pfizer said two months ago that it would close a 55-year-old plant in Thane, India, that it no longer wanted. But someone sees some value in it, and the U.S. drugmaker now says the facility will be sold to an Indian operation for nearly $27 million.
In May, Russia's Generium said it would build a massive blood plasma plant in the country, to make antibodies, blood coagulants and albumin. Now a Swedish design firm said it starting on on the engineering for the project.